Thomas Schlake
Overview
Explore the profile of Thomas Schlake including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rauch S, Lutz J, Muhe J, Kowalczyk A, Schlake T, Heidenreich R
Methods Mol Biol
. 2024 May;
2786:183-203.
PMID: 38814395
Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we...
2.
Hauser S, Poenisch M, Schelling Y, Hoflinger P, Schuster S, Teegler A, et al.
Mol Ther Methods Clin Dev
. 2019 Dec;
15:359-370.
PMID: 31828178
Hereditary spastic paraplegia type 5 is a neurodegenerative disease caused by loss-of-function mutations in the gene encoding the oxysterol 7-α-hydroxylase involved in bile acid synthesis in the liver. Lack of...
3.
Schlake T, Thran M, Fiedler K, Heidenreich R, Petsch B, Fotin-Mleczek M
Mol Ther
. 2019 Mar;
27(4):773-784.
PMID: 30885573
First attempts to use exogenous mRNA for protein expression in vivo were made more than 25 years ago. However, widespread appreciation of in vitro transcribed mRNA as a powerful technology...
4.
Schlake T, Thess A, Thran M, Jordan I
Cell Mol Life Sci
. 2018 Oct;
76(2):301-328.
PMID: 30334070
While active immunization elicits a lasting immune response by the body, passive immunotherapy transiently equips the body with exogenously generated immunological effectors in the form of either target-specific antibodies or...
5.
Thran M, Mukherjee J, Ponisch M, Fiedler K, Thess A, Mui B, et al.
EMBO Mol Med
. 2017 Aug;
9(10):1434-1447.
PMID: 28794134
The delivery of genetic information has emerged as a valid therapeutic approach. Various reports have demonstrated that mRNA, besides its remarkable potential as vaccine, can also promote expression without inducing...
6.
Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R
Methods Mol Biol
. 2016 Dec;
1499:89-107.
PMID: 27987144
Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we...
7.
Thess A, Grund S, Mui B, Hope M, Baumhof P, Fotin-Mleczek M, et al.
Mol Ther
. 2015 Jun;
23(9):1456-64.
PMID: 26050989
Being a transient carrier of genetic information, mRNA could be a versatile, flexible, and safe means for protein therapies. While recent findings highlight the enormous therapeutic potential of mRNA, evidence...
8.
Kallen K, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, et al.
Hum Vaccin Immunother
. 2013 Aug;
9(10):2263-76.
PMID: 23921513
Nucleotide based vaccines represent an enticing, novel approach to vaccination. We have developed a novel immunization technology, RNActive(®) vaccines, that have two important characteristics: mRNA molecules are used whose protein...
9.
Petsch B, Schnee M, Vogel A, Lange E, Hoffmann B, Voss D, et al.
Nat Biotechnol
. 2012 Nov;
30(12):1210-6.
PMID: 23159882
Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable...
10.
Schlake T, Thess A, Fotin-Mleczek M, Kallen K
RNA Biol
. 2012 Oct;
9(11):1319-30.
PMID: 23064118
mRNA vaccines combine desirable immunological properties with an outstanding safety profile and the unmet flexibility of genetic vaccines. Based on in situ protein expression, mRNA vaccines are capable of inducing...